208 related articles for article (PubMed ID: 37267108)
1. Mutant IDH regulates glycogen metabolism from early cartilage development to malignant chondrosarcoma formation.
Pathmanapan S; Poon R; De Renshaw TB; Nadesan P; Nakagawa M; Seesankar GA; Ho Loe AK; Zhang HH; Guinovart JJ; Duran J; Newgard CB; Wunder JS; Alman BA
Cell Rep; 2023 Jun; 42(6):112578. PubMed ID: 37267108
[TBL] [Abstract][Full Text] [Related]
2. Distinct Roles of Glutamine Metabolism in Benign and Malignant Cartilage Tumors With IDH Mutations.
Zhang H; Puviindran V; Nadesan P; Ding X; Shen L; Tang YJ; Tsushima H; Yahara Y; Ban GI; Zhang GF; Karner CM; Alman BA
J Bone Miner Res; 2022 May; 37(5):983-996. PubMed ID: 35220602
[TBL] [Abstract][Full Text] [Related]
3. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours.
Amary MF; Bacsi K; Maggiani F; Damato S; Halai D; Berisha F; Pollock R; O'Donnell P; Grigoriadis A; Diss T; Eskandarpour M; Presneau N; Hogendoorn PC; Futreal A; Tirabosco R; Flanagan AM
J Pathol; 2011 Jul; 224(3):334-43. PubMed ID: 21598255
[TBL] [Abstract][Full Text] [Related]
4. IDH1 Mutation Induces HIF-1
Hu X; Li L; Eid JE; Liu C; Yu J; Yue J; Trent JC
Dis Markers; 2022; 2022():7729968. PubMed ID: 35198082
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.
Suijker J; Oosting J; Koornneef A; Struys EA; Salomons GS; Schaap FG; Waaijer CJ; Wijers-Koster PM; Briaire-de Bruijn IH; Haazen L; Riester SM; Dudakovic A; Danen E; Cleton-Jansen AM; van Wijnen AJ; Bovée JV
Oncotarget; 2015 May; 6(14):12505-19. PubMed ID: 25895133
[TBL] [Abstract][Full Text] [Related]
6. Genomic Profiling Identifies Association of
Zhu GG; Nafa K; Agaram N; Zehir A; Benayed R; Sadowska J; Borsu L; Kelly C; Tap WD; Fabbri N; Athanasian E; Boland PJ; Healey JH; Berger MF; Ladanyi M; Hameed M
Clin Cancer Res; 2020 Jan; 26(2):419-427. PubMed ID: 31615936
[TBL] [Abstract][Full Text] [Related]
7. Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals TP53 Mutation to Be Associated with Worse Outcomes.
Denu RA; Yang RK; Lazar AJ; Patel SS; Lewis VO; Roszik J; Livingston JA; Wang WL; Shaw KR; Ratan R; Zarzour MA; Bird J; Raza S; Akdemir KC; Rodon Ahnert J; Subbiah V; Patel S; Conley AP
Clin Cancer Res; 2023 Dec; 29(23):4844-4852. PubMed ID: 37747813
[TBL] [Abstract][Full Text] [Related]
8. IDH mutation status in a series of 88 head and neck chondrosarcomas: different profile between tumors of the skull base and tumors involving the facial skeleton and the laryngotracheal tract.
Tallegas M; Miquelestorena-Standley É; Labit-Bouvier C; Badoual C; Francois A; Gomez-Brouchet A; Aubert S; Collin C; Tallet A; de Pinieux G
Hum Pathol; 2019 Feb; 84():183-191. PubMed ID: 30296521
[TBL] [Abstract][Full Text] [Related]
9. Intracellular cholesterol biosynthesis in enchondroma and chondrosarcoma.
Zhang H; Wei Q; Tsushima H; Puviindran V; Tang YJ; Pathmanapan S; Poon R; Ramu E; Al-Jazrawe M; Wunder J; Alman BA
JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31039139
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of IDH mutations in chondrosarcoma.
Nakagawa M; Sekimizu M; Endo M; Kobayashi E; Iwata S; Fukushima S; Yoshida A; Kitabayashi I; Ichikawa H; Kawai A; Nakatani F
J Orthop Sci; 2022 Nov; 27(6):1315-1322. PubMed ID: 34531086
[TBL] [Abstract][Full Text] [Related]
11. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells.
Li L; Paz AC; Wilky BA; Johnson B; Galoian K; Rosenberg A; Hu G; Tinoco G; Bodamer O; Trent JC
PLoS One; 2015; 10(9):e0133813. PubMed ID: 26368816
[TBL] [Abstract][Full Text] [Related]
12. Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma.
Nakagawa M; Nakatani F; Matsunaga H; Seki T; Endo M; Ogawara Y; Machida Y; Katsumoto T; Yamagata K; Hattori A; Fujita S; Aikawa Y; Ishikawa T; Soga T; Kawai A; Chuman H; Yokoyama N; Fukushima S; Yahiro K; Kimura A; Shimada E; Hirose T; Fujiwara T; Setsu N; Matsumoto Y; Iwamoto Y; Nakashima Y; Kitabayashi I
Oncogene; 2019 Oct; 38(42):6835-6849. PubMed ID: 31406254
[TBL] [Abstract][Full Text] [Related]
13. IDH1 mutations are not found in cartilaginous tumours other than central and periosteal chondrosarcomas and enchondromas.
Damato S; Alorjani M; Bonar F; McCarthy SW; Cannon SR; O'Donnell P; Tirabosco R; Amary MF; Flanagan AM
Histopathology; 2012 Jan; 60(2):363-5. PubMed ID: 22074484
[No Abstract] [Full Text] [Related]
14. Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma.
Mohammad N; Wong D; Lum A; Lin J; Ho J; Lee CH; Yip S
Histopathology; 2020 Apr; 76(5):722-730. PubMed ID: 31609487
[TBL] [Abstract][Full Text] [Related]
15. The biology and management of cartilaginous tumors: a role for targeting isocitrate dehydrogenase.
Tinoco G; Wilky BA; Paz-Mejia A; Rosenberg A; Trent JC
Am Soc Clin Oncol Educ Book; 2015; ():e648-55. PubMed ID: 25993236
[TBL] [Abstract][Full Text] [Related]
16. Frequent IDH1/2 mutations in intracranial chondrosarcoma: a possible diagnostic clue for its differentiation from chordoma.
Arai M; Nobusawa S; Ikota H; Takemura S; Nakazato Y
Brain Tumor Pathol; 2012 Oct; 29(4):201-6. PubMed ID: 22323113
[TBL] [Abstract][Full Text] [Related]
17. Distinct IDH1/2-associated Methylation Profile and Enrichment of
Dermawan JKT; Nafa K; Mohanty A; Xu Y; Rijo I; Casanova J; Villafania L; Benhamida J; Kelly CM; Tap WD; Boland PJ; Fabbri N; Healey JH; Ladanyi M; Lu C; Hameed M
Cancer Res Commun; 2023 Mar; 3(3):431-443. PubMed ID: 36926116
[TBL] [Abstract][Full Text] [Related]
18. Mutant IDH is sufficient to initiate enchondromatosis in mice.
Hirata M; Sasaki M; Cairns RA; Inoue S; Puviindran V; Li WY; Snow BE; Jones LD; Wei Q; Sato S; Tang YJ; Nadesan P; Rockel J; Whetstone H; Poon R; Weng A; Gross S; Straley K; Gliser C; Xu Y; Wunder J; Mak TW; Alman BA
Proc Natl Acad Sci U S A; 2015 Mar; 112(9):2829-34. PubMed ID: 25730874
[TBL] [Abstract][Full Text] [Related]
19. Mutant IDH and non-mutant chondrosarcomas display distinct cellular metabolomes.
Pathmanapan S; Ilkayeva O; Martin JT; Loe AKH; Zhang H; Zhang GF; Newgard CB; Wunder JS; Alman BA
Cancer Metab; 2021 Mar; 9(1):13. PubMed ID: 33762012
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone.
Chen S; Fritchie K; Wei S; Ali N; Curless K; Shen T; Brini AT; Latif F; Sumathi V; Siegal GP; Cheng L
Hum Pathol; 2017 Jul; 65():239-246. PubMed ID: 28552826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]